Abstract
Pancreatic ductal adenocarcinoma (PDAC) represents the majority of diagnosed pancreatic cancers and its mortality rates are well above 90%. This bleak scenario is mostly due to its very difficult early diagnosis, scarce surgical treatability, high relapse rate and poor response to systemic and targeted therapies. Apparently, an imbalance between male and female incidence of PDAC could suggest some sort of “protective mechanism” in women against the onset of this neoplasia, possibly played by estrogen receptors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
